Telix Pharmaceuticals
21 hedge funds and large institutions have $7.29M invested in Telix Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 1
812% more capital invested
Capital invested by funds: $799K → $7.29M (+$6.49M)
250% more funds holding
Funds holding: 6 → 21 (+15)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.12% more ownership
Funds ownership: 0.01% → 0.14% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
+$3.17M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$707K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$694K |
| 5 |
Jane Street
New York
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
ABC Arbitrage
Paris,
France
|
-$451K |
| 2 |
Morgan Stanley
New York
|
-$20.7K |
| 3 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$1.18K |
TLX Hedge Fund Activity: Q2 2025 in Review
21 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q2 2025, worth a combined $7.29M — up 812% from $799K a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TLX positions and 1 closed out — a net gain of 15 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Pier Capital, opening a new position worth an estimated $3.17M. The largest seller was ABC Arbitrage, exiting entirely with an estimated $451K sold.
- 21 institutional investors held Telix Pharmaceuticals (TLX) as of Q2 2025, up from 6 in Q1 2025.
- Funds reported $7.29M of Telix Pharmaceuticals stock for Q2 2025, up 812% quarter-over-quarter.
- 16 funds opened new Telix Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of +15 holders.
- The largest Telix Pharmaceuticals buyer in Q2 2025 was Pier Capital, an estimated $3.17M added.
- The largest Telix Pharmaceuticals seller in Q2 2025 was ABC Arbitrage, an estimated $451K sold.
Based on aggregated 13F filings for Q2 2025.